Recker is perhaps best known for a study in which he, molecular geneticist Mark Johnson and several others found a gene mutation causing bones to be twice as massive as “normal” bones. Using the genetic material from these “super bones” that were discovered virtually by accident in a Nebraska-based family, the two have been working on what some might call “nature’s cure” for osteoporosis.
Adolescent Medicine ExpertAnn and Robert H. Lurie Children's Hospital of Chicago
Lgbt, transgender children, Adolescent Medicine, Sexuality, HIV
Robert Garofalo, MD, MPH, is the Division Head of Adolescent Medicine at Ann & Robert H. Lurie Children’s Hospital of Chicago and a Professor of Pediatrics at Northwestern University Feinberg School of Medicine. He is a Co-Director of Lurie Children’s Gender and Sex Development Program, the first comprehensive program for gender nonconforming children and adolescents in the Midwest. Dr. Garofalo also directs Lurie Children’s Adolescent/Young Adult HIV Program and the Center for Gender, Sexuality and HIV Prevention, which conducts research on topics in adolescent sexual health, gender, sexuality, HIV prevention and health disparities affecting adolescent and young adult populations at risk of acquiring HIV. He is a national expert on lesbian, gay, bisexual and transgender (LGBT) health issues in youth, as well as adolescent sexuality and HIV clinical care and prevention. Dr. Garofalo is the former President of the Gay and Lesbian Medical Association. In 2010, he served as a committee member for the National Academy of Sciences/Institute of Medicine Committee on Lesbian, Gay, Bisexual and Transgender Health Issues and Research Gaps and Opportunities.
Dr. Herbst’s primary mission is the enhanced integration of clinical, laboratory, and research programs to bring new treatments to cancer patients. He has led the Phase I development of several of the new generation of targeted agents for non-small cell lung cancer (NSCLC), including gefitinib, erlotinib, cetuximab, and bevacizumab. More recently, he participated in the successful registration of pembrolizumab for the treatment of advanced non-small cell lung cancer, following the successful Yale-led KEYNOTE 10 study of the immune therapy drug commonly used to treat other cancers. He was co-leader for the BATTLE-1 clinical trial program, co-leads the subsequent BATTLE-2 clinical trial program, and served as a Co-program Leader of the Developmental Therapeutics Program for the YCC Support Grant. Dr. Herbst’s laboratory work is focused on immunotherapy angiogenesis; dual epidermal growth factor receptor (EGFR)/vascular endothelial growth factor receptor (VEGFR) inhibition in NSCLC, and targeting KRAS-activated pathways. More recently, he has explored predictive biomarkers for the use of immunotherapy agents. This work has been translated from the preclinical to clinical setting in multiple Phase II and III studies which he has led. After earning a B.S. and M.S. degree from Yale University, Dr. Herbst earned his M.D. at Cornell University Medical College and his Ph.D. in molecular cell biology at The Rockefeller University in New York City, New York. His postgraduate training included an internship and residency in medicine at Brigham and Women’s Hospital in Boston, Massachusetts. His clinical fellowships in medicine and hematology were completed at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital, respectively. Subsequently, Dr. Herbst completed a M.S. degree in clinical translational research at Harvard University in Cambridge, Massachusetts. Dr. Herbst is an author or co-author of more than 275 publications, including peer-reviewed journal articles, abstracts, and book chapters. His work has been published in many prominent journals, such as the Journal of Clinical Oncology, Clinical Cancer Research, Lancet, the New England Journal of Medicine, and Nature. His abstracts have been presented at the annual meetings of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the World Conference on Lung Cancer, the Society of Nuclear Medicine Conference, and the European Organization for Research and Treatment of Cancer. Dr. Herbst was a member of the National Cancer Policy Forum (1998-2014) for which he organized an Institute of Medicine meeting focused on policy issues in personalized medicine. He is a member of ASCO and, as a member of AACR, he chairs the Tobacco Task Force. He is a fellow of the American College of Physicians and an elected member of the Association of American Physicians. Dr. Herbst is also a member of the medical advisory committee for the Lung Cancer Research Foundation and chair of the communications committee for ASCO and the International Association for the Study of Lung Cancer. He is currently the Vice Chair for Developmental Therapeutics for the Southwestern Oncology Group (SWOG) Lung Committee, Principal Investigator of the SWOG 0819 trial, and steering committee chair for the Lung Master Protocol (Lung MAP). Dr. Herbst was awarded the 2010 Waun Ki Hong Award for Excellence in Team Science by the Division of Cancer Medicine, UT-MDACC. The Alvin S. Slotnick Lecture Award for notable contributions to lung cancer research was bestowed upon him by Dana-Farber/Brigham and Women’s Cancer Center in 2014. That same year, the Bonnie Addario Foundation honored him with the Annual Addario Lectureship Award and the Bonnie J. Addario Excellence in Collaboration and Innovation Award. In 2015, the Clinical Research Forum presented his project “Predictive Correlates of Response to the Anti-PD-L1 Antibody MPDL3280A in Cancer Patients” its top Clinical Research Achievement Award in the United States for 2015. For his lifetime achievement in scientific contributions to thoracic cancer research, Herbst was awarded the 2016 Paul A. Bunn, Jr. Scientific Award by the International Association for the Study of Lung Cancer at IASLC 17th World Conference on Lung Cancer in Vienna, Austria. His work has been funded by ASCO, AACR, the United States Department of Defense, and the National Cancer Institute. In 2015, his team at Yale was awarded a lung cancer SPORE by the NCI, and he serves as a principal investigator for the AACR/ Stand Up to Cancer Dream Team grant. EDUCATION & TRAINING MMS Harvard University, Clinical Translational Research (1997) MD Cornell University Medical College (1991) PhD Rockefeller University (1990) BS Yale University, Molecular Biophysics & Biochemistry (1984) MS Yale University, Molecular Biophysics and Biochemistry (1984) Fellowship Brigham and Women`s Hospital Fellowship Dana Farber Cancer Institute Residency Brigham and Women`s Hospital HONORS & RECOGNITION Elected to the Association of American Physicians AAP (2015) Addario Foundation Lectureship Award Bonnie Addario Foundation (2014) Alvin S. Slotnick Lecture Award for notable contributions to lung cancer research Dana-Farber/Brigham and Women’s Cancer Center (2014) Best Doctors, New York Magazine (2014) Honorary Professor, University College London Cancer Center University College London (2012) Sikand Orator Yale University (2011) PROFESSIONAL SERVICE National Cancer Institute (2012 - Present) Thoracic Malignancy Steering Committee - National Cancer Institute
Roy A. Jensen, M.D. earned his bachelor’s degree in Biology and Chemistry from Pittsburg State University in 1980. He graduated from Vanderbilt University School of Medicine in 1984, and remained there to complete a residency in Anatomic Pathology and a Surgical Pathology fellowship under the direction of Dr. David L. Page. Following his clinical training he accepted a biotechnology training fellowship at the National Cancer Institute in the laboratory of Dr. Stuart Aaronson. He returned to Vanderbilt in 1991 and was appointed an assistant professor in the Departments of Pathology and Cell Biology. In 1993 Dr. Jensen was appointed as an investigator in the Vanderbilt-Ingram Cancer Center and assumed the management of the Human Tissue Acquisition and Pathology Shared Resource. Dr. Jensen was promoted to associate professor of Pathology and Cell Biology in 1996, and was appointed as an associate professor of Cancer Biology in 2001. In 2004, Dr. Jensen returned home to Kansas and was appointed the William R. Jewell, M.D. Distinguished Kansas Masonic Professor, the director of The University of Kansas Cancer Center, the director of the Kansas Masonic Cancer Research Institute, professor of Pathology and Laboratory Medicine, and professor of Anatomy and Cell Biology at the University of Kansas Medical Center. He also holds appointments as a professor in the Department of Molecular Biosciences at the University of Kansas-Lawrence and as professor in Cancer Biology at The University of Kansas Medical Center. Dr. Jensen is currently serving as president of the Association of American Cancer Institutes (AACI) and is a member of several scientific and professional societies including the American Association for Cancer Research, the American Association for the Advancement of Science, the American Society for Cell Biology, the American Society for Investigative Pathology, and the United States and Canadian Academy of Pathology. He currently has over 150 scientific publications and has lectured widely on the clinical and molecular aspects of breast cancer pathology. Dr. Jensen's research interests are focused on understanding the function of BRCA1 and BRCA2 and their role in breast and ovarian neoplasia; and in the characterization of premalignant breast disease both at the morphologic and molecular levels. His laboratory was instrumental in demonstrating the role of BRCA1 in the growth control of normal and malignant cells and in how loss of functional BRCA1 contributes to the development of breast cancer. Since becoming director of The University of Kansas Cancer Center in 2004, he has recruited a world-class leadership team and successfully led that team in achieving designation for The University of Kansas Cancer Center as a National Cancer Institute designated cancer center.
Food Allergy ExpertAnn and Robert H. Lurie Children's Hospital of Chicago
Food Allergy, Food Allergies, Asthma
Ruchi Gupta, MD, is an Attending Physician, Academic General Pediatrics and Primary Care, at Ann & Robert H. Lurie Children’s Hospital of Chicago and an Associate Professor of Pediatrics at Northwestern University Feinberg School of Medicine. Dr. Gupta also is the Director of the Science and Outcomes of Allergy and Asthma Research Team (SOAAR). Her clinical interests are in the areas of asthma, food allergy, and eczema. She is involved in clinical, epidemiological, and community research. She has been nationally recognized for her research in the areas of food allergy and asthma epidemiology.
Director of Nutrition Services/Community OutreachAmerican Association of Diabetes Educators (AADE)
Diabetes, Type 2 Diabetes, Diabetes Self-management, Diabetes and Adults, Diabetes and Latino, hispanic health risk factors, Hispanic Health, Bronx and Brooklyn, Latino Health, Minority Health, Minority Health and Health Equity, Health Literacy, Nutrition,
Aging, Gerontolgoy, Aging In Place, Housing, housing access, Older Adults, Nursing Home, Community Health, Occupational Therapist, health disparites, Health Policy, Nurse Practitioner, Homebound Patients, low-income communities, health care savings, Nurse,
A number of years ago, while making house calls as a nurse practitioner to homebound, low-income elderly patients in West Baltimore, Sarah Szanton noticed that their environmental challenges were often as pressing as their health challenges. Since then she has developed a program of research at the Johns Hopkins School of Nursing on the role of the environment and stressors in health disparities in older adults, particularly those trying to “age in place” or stay out of a nursing home. The result is a program called CAPABLE, which combines handyman services with nursing and occupational therapy to improve mobility, reduce disability, and decrease healthcare costs. She is currently examining the program's effectiveness through grants from the National Institutes of Health and the Innovations Office at the Center on Medicaid and Medicare Services. She is also conducting a study, funded by the Robert Wood Johnson Foundation, of whether food and energy assistance improve health outcomes for low-income older adults. A former health policy advocate, Dr. Szanton aims her research and publications toward changing policy for older adults and their families.
Dr. Crotty received his B.S. in Biology from the Massachusetts Institute of Technology (MIT) in 1996. He also received a B.S. in Writing from MIT the same year. Dr. Crotty undertook graduate work in virology at the University of California, San Francisco in the Program in Biological Sciences. There he discovered the mechanism of action of the antiviral drug ribavirin, widely used to treat chronic hepatitis C infections. Dr. Crotty earned his Ph.D. in Biochemistry and Molecular Biology in 2001. He then pursued postdoctoral work at the Emory University Vaccine Center with Dr. Rafi Ahmed from 2001 to 2003, studying aspects of the generation and maintenance of immune memory after viral infections. In 2003, he accepted a faculty position at LJI. The Crotty lab has helped established that follicular helper T cells (Tfh) are a distinct type of differentiated CD4 T cell uniquely specialized in B cell help, and that Tfh differentiation is controlled by the transcription factor Bcl6 (Science 2009). He has made major advances in the area of T cell help to B cells, and through this work has become an internationally recognized leader in the field of Tfh cell biology (Annual Review of Immunology 2011). Dr. Crotty was named a Pew Scholar in Biomedical Sciences in 2005, and was the recipient of the annualAmerican Association of Immunologists (AAI) Investigator Award for outstanding early-career research contributions to the field of Immunology in 2012. Dr. Crotty is also the author of Ahead of the Curve, a biography of Nobel laureate scientist David Baltimore, published in 2001, and reviewed in The Wall Street Journal, Nature, The Washington Post, The Journal of the American Medical Association (JAMA), Nature Medicine, and Discover Magazine.
Stephen Mosher is a professor of sport management and media. Mosher has coached youth sports himself for over 25 years and studies the issues of sport in popular culture. He is currently working on an ethnography of bowling, which discusses how that sport plays a central role in the civic engagement of blue collars workers. In 2001, he wrote a series of columns for ESPN.com on the Little League World Series scandal involving pitcher Danny Almonte, who played despite being two years over the age limit.
Dr. Steve Hodges, a pediatric urologist who practices in Winston-Salem, NC, is a leading expert when it comes to children and issues related to toilet training, bedwetting and constipation. His own published research shows that children trained before age 2 have a much higher risk of having accidents compared to those trained later and are more likely to become habitual holders of their pee and poop, which can lead to issues with constipation. Hodges can discuss how today's today’s modern parents feel societal and financial pressure to toilet train their children before they are developmentally and physically ready. In his opinion, few children are ready to be fully toilet trained before the age of 3. He can discuss how diet affects children's bowel systems: what goes in (food) determines what comes out (poop). A diet full of highly processed foods like crackers, chicken nuggets and hotdogs without lots of vegetables, fruits and fibers often leads to constipation. Hodges can discuss how improper poop or pee posture can affect children's ability to fully eliminate: When it comes to pooping, it’s not enough to have a cute little seat in place because a “squatting” position improves childrens’ ability to fully eliminate. They need to sit on the toilet with their feet on a tall stool, leaning forward, elbows on knees. And, he can address how parents and caregivers should not ASK if their child has to go to the bathroom because they will likely say NO because they don’t want to stop whatever activity they are involved in. Instead, children should be directed to attempt to pee about every two hours and should be encouraged in a way that works for them individually. When children hold their pee at this young age, this actually leads to smaller bladder capacity which can lead to problems like bedwetting.
Dr. Tardif is Associate Director of Research and Senior Management Team member for SNPRC and has extensive experience coordinating large, integrated research projects throughout her professional career. She served as the marmoset expert for the team charged with sequencing the marmoset genome and as the species expert for recent studies on development of induced pluripotent stem cell (iPS cell) technologies. Her research is focused on metabolism, behavior and reproduction and, most recently, on the characterization of the marmoset as a model for obesity and aging. Dr. Tardif has more than 30 years of expertise in the development of common marmoset monkeys as biomedical models in diverse areas including: Reproductive biology Infectious disease Neuroscience Aging and obesity
Tom Greenfield, PhD, is Scientific Director of the Public Health Institute’s Alcohol Research Group, in Emeryville California, which involves 15 multi-disciplinary research scientists bringing a broad range of expertise to bear on alcohol, other drug and mental health problems. Since 1995 Greenfield led and now co-lead the bi-decadal National Alcohol Surveys (NASs) conducted by the NIAAA-funded National Alcohol Research Center, that he directed from 1999 to 2015 (P50 AA005595, Years 20-35). Over time, the NAS has incorporated measures and interview modalities that he helped refine in a series of methodological studies. Greenfield trained as a clinical psychologist, afterwards adding epidemiological and health services expertise in part through postdoctoral years at the UCSF Department of Psychiatry. Educated at Caltech, MIT and the University of Michigan, he has authored or coauthored over 250 peer-reviewed articles, chapters, books and monographs. Many are on health effects of alcohol and alcohol policy, often in collaboration with senior colleagues, early career scientists, and postdoctoral fellows. In addition to participating in many national and international projects, Dr. Greenfield has led numerous R-mechanism National Institutes of Health projects on such topics as alcohol policy evaluation, health disparities and alcohol-related mortality, alcohol intake measurement, and comparative cross-national studies. He currently leads two team-based Alcohol's Harms to Others R01 grants funded by NIAAA. One, together with his ARG colleague Dr. Katherine Karriker-Jaffe, examines ways that secondhand drinking can victimize partners, families, children, coworkers, and communities, using metrics such as the damage to mental health, health quality of life, and a family’s finances. A second is a similar multinational collaboration involving standardized questionnaires in over 30 countries that surveyed victims and perpetrators of alcohol’s harms, and involves multiple PIs and 15 international co-investigators. Both grants are examining in depth state and national policies, contextual, and protective influences, and ways to best reduce the toll of alcohol’s harms to communities. Selected recent publications: Wilsnack, S.C., Greenfield, T.K., Bloomfield, K.A., (in press). The GENAHTO Project (Gender and Alcohol's Harm to Others): design and methods for a multinational study of alcohol's harm to persons other than the drinker. International Journal of Alcohol & Drug Research. Greenfield, T. K. & Martinez, P. (2017) Alcohol as a risk factor for chronic disease: raising awareness and policy options. In: Giesbrecht, N. & Bosma, L. (Eds.), Preventing Alcohol-Related Problems: Evidence and Community-based Initiatives (pp 33-50). Washington, DC: APHA Press. Greenfield, T.K., Ye, Y., Lown, E.A., Cherpitel, C.J., Zemore, S., & Borges, G. (2017) Alcohol use patterns and DSM-5 alcohol use disorder on both sides of the US-Mexico border. Alcoholism: Clinical & Experimental Research 41:769-778. [DOI: 10.1111/acer.13356] PMICD: PMC5378627 Greenfield, T.K., Karriker-Jaffe, K.J., Kerr, W.C., Ye, Y., & Kaplan, L.M. (2016) Those harmed by others’ drinking are more depressed and distressed, Drug and Alcohol Review, 35(1):22-29 [doi: 10.1111/dar.12324]. PMCID: PMC4775452 Greenfield, T.K., Bond J., Kerr W.C. (2014) Biomonitoring for improving alcohol consumption surveys: the new gold standard? Alcohol Research: Current Reviews 36(1): 39-44. PMCID: PMC4432857 Greenfield, T. K. (2013) [Editorial] Alcohol (and other drugs) in public health research. American Journal of Public Health 103(4):582.
Timothy McBride is an influential health policy analyst and leading health economist shaping the national agenda in health insurance, health reform, rural health care, Medicare and Medicaid policy, health economics, and access to health care. McBride studies the effects of health reform at the state and national levels, the uninsured, diabetes policy, Medicare Advantage, and long-term entitlement reform. McBride has been active in testifying before Congress and consulting with policy constituents on health reform, health insurance issues and rural health policy. He is a member of the Rural Policy Research Institute Health Panel that provides expert advice on rural health issues to the U.S. Congress and other policymakers.
Global and Infectious Diseases Fellow at the O’Neill Institute. Prior to joining the O’Neill Institute, Tom worked as an epidemiologist, focusing on infectious diseases such as HIV, Lassa, and Ebola. His work has taken him to Sierra Leone and Uganda, where he organized and trained African public health professionals on field epidemiology, Lassa, and other viral hemorrhagic fevers. Vincent can discuss infectious disease epidemiology and global public health.